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ABSTRACT
Background: Previous studies have reported an inter-
action between ever cigarette smoking and the presence
of the human leukocyte antigen (HLA)-DRB1 shared
epitope (SE) genotype and rheumatoid arthritis (RA) risk.
To address the effect of dosage, a case-control study
nested within two prospective cohorts to determine the
interaction between heavy smoking and the HLA-SE was
conducted.
Methods: Blood was obtained from 32 826 women in
the Nurses’ Health Study and 29 611 women in the
Nurses’ Health Study II. Incident RA diagnoses were
validated by chart review. Controls were matched for age,
menopausal status and postmenopausal hormone use.
High-resolution HLA-DRB1 genotyping was performed for
SE alleles. HLA-SE, smoking, HLA-SE* smoking interac-
tions and RA risk, were assessed using conditional logistic
regression models, adjusted for age and reproductive
factors. Additive and multiplicative interactions were
tested.
Results: In all, 439 Caucasian matched pairs were
included. Mean age at RA diagnosis was 55.2 years; 62%
of cases were seropositive. A modest additive interaction
was observed between ever smoking and HLA-SE in
seropositive RA risk. A strong additive interaction
(attributable proportion due to interaction (AP)=0.50;
p,0.001) and significant multiplicative interaction
(p=0.05) were found between heavy smoking (.10
pack-years) and any HLA-SE in seropositive RA risk. The
highest risk was in heavy smokers with double copy HLA-
SE (odds ratio (OR) 7.47, 95% CI 2.77 to 20.11).
Conclusions: A strong gene–environment interaction
was observed between HLA-SE and smoking when
stratifying by pack-years of smoking rather than by ever
smoking. Future studies should assess cumulative
exposure to cigarette smoke when testing for gene–
smoking interactions.
Rheumatoid arthritis (RA), an autoimmune disease
of unknown aetiology, affects approximately 1% of
the adult population.
1 Genetic and environmental
factors are thought to interact in RA development.
Epidemiological research has demonstrated a
strong association between cigarette smoking and
RA risk.
2–14 In the Nurses’ Health Study (NHS), we
have found that RA risk is significantly elevated
among women with .10 pack-years of smoking,
and a strong dose-response exists.
12 14
The strongest genetic risk factor for RA is found
within the human leukocyte antigen (HLA) com-
plex (or major histocompatibility complex antigen
(MHC)). Within the HLA class II region, multiple
HLA-DRB1 alleles are associated with RA.
15–17 In
individuals of European ancestry, the associated
HLA-DRB1 alleles share a region of sequence
similarity or ‘‘shared epitope’’ (SE) at amino acid
positions 70–74 in the third hypervariable region of
the HLA-DRB1 molecule.
18 Smoking and HLA
shared epitope (HLA-SE) genotypes interact to
increase risk of seropositive but not seronegative
RA in several studies.
13 19–21 However, the dose
effect aspects of this interaction have not been
studied. One study of three North American RA
cohorts
22 did not demonstrate a significant inter-
action between ever smoking and HLA-SE in
predicting anti-cyclic citrullinated protein (CCP)
antibodies or rheumatoid factor (RF) among RA
cases.
19
We studied the interaction between HLA-SE
alleles and smoking dose among women in a case-
control study nested within two large prospective
cohort studies, the Nurses’ Health Studies. We
aimed to determine whether heavier smoking was
associated with a stronger gene–environment
interaction than was ever smoking.
METHODS
Study population
The NHS is a prospective cohort of 121 700 female
nurses, aged between 30–55 years in 1976. From
1989 to 1990, 32 826 (27%) NHS participants ages
43–70 provided blood samples. The Nurses’ Health
Study II (NHSII) is a similar cohort, with 116 608
female nurses aged between 25–42 in 1989.
Between 1996 and 1999, 29 611 (25%) of the
women participating in NHSII cohort, aged 32–52
at that time, provided blood samples. The demo-
graphics and exposure characteristics of partici-
pants who provided blood samples are similar to
those of the overall cohorts.
23 24 All aspects of this
study were approved by the Partners’ HealthCare
Institutional Review Board.
Identification of rheumatoid arthritis
As previously described,
14 we confirmed self-reports
of RA based on presence of RA symptoms on a
connective tissue disease screening questionnaire
(CSQ),
25 and, medical record review for four or
more of the seven American College of
Rheumatology (ACR) classification criteria for
RA.
26 We included a small number of subjects
(n=14) with agreement by two rheumatologist
reviewers on diagnosis of RA, three documented
ACR criteria for RA and a diagnosis of RA by their
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self-reports was 77%, and 96% to requests for medical records.
Population for analysis
For cases and controls, we excluded women who reported any
cancer (except non-melanoma skin cancer) at baseline or during
follow-up. Each participant with RA was matched by year of
birth, race/ethnicity, menopausal status and postmenopausal
hormone use to a single healthy woman in the same cohort
without RA. To minimise potential population stratification,
we limited the analyses to Caucasian women.
DNA extraction and amplification
DNA was extracted from buffy coats and processed via the
QIAmp (Qiagen, Chatsworth, California, USA) 96-spin blood
kit protocol as previously described.
27 All genomic DNA samples
had an aliquot put through a whole genome amplification
protocol using the GenomPhi DNA amplification kit (GE
Healthcare, Piscataway, New Jersey, USA) to yield high quality
DNA sufficient for HLA genotyping.
Seropositive phenotyping
We collected information on RF from medical records reviewed
from the date of RA diagnosis. We did not have records from later
in the disease course, or information on CCP as cases were
diagnosed prior to its widespread use. For a subset of 180 NHS
and 41 NHSII RA cases, plasma samples were collected in 1989
and a second set of plasma samples collected in 2000. In all, 98
samples were collected before RA diagnosis (incident samples)
and 123 were collected after diagnosis (prevalent samples). We
used the DIASTAT CCP (Axis-Shield Diagnostics, Dundee, UK)
second-generation test, a semiquantitative/qualitative ELISA for
detection of IgG CCP antibodies. A CCP antibody titre .5U / m l
was considered positive according to the manufacturer’s estab-
lished threshold. Since prior work from Sweden has demon-
strated gene–environment interactions between HLA-SE and
smoking for RF-positive
13 and CCP-positive RA,
19 we created a
combination phenotype based on RF results from the medical
record supplemented by CCP results from plasma samples where
available, as ‘‘ever seropositive’’ versus ‘‘never seropositive’’.
HLA-SE determination
Low-resolution HLA-DRB1 genotyping was performed using
polymerase chain reaction with sequence specific primers (PCR-
SSP) using OLERUP SSP kits (Qiagen, West Chester,
Pennsylvania, USA). We used primers to amplify DNA samples
that contained sequences for HLA-DRB1*04, *01,*10 and *14,
along with consensus primers and appropriate positive and
negative control samples. For samples with positive two-digit
HLA signals, sequence specific primers were used for high-
resolution four-digit shared epitope allele detection of
DRB1*0401, *0404, *0405, *0101, *0102, *1402 and *1001.
OLERUP SSP computer software (Qiagen) was used to
determine four-digit HLA types.
Covariates
Information was collected via prospective biennial subject
questionnaires regarding diseases, lifestyle and health practices.
Reproductive covariates were chosen based on associations
between reproductive factors and the RA risk in this cohort.
28
Lifetime smoking history was collected at baseline and updated
data concerning current smoking and number of cigarettes
smoked a day were collected every 2 years. Data on smoking,
parity, total duration of breast feeding, menopausal status and
postmenopausal hormone use were selected from the cycle prior
to the RA diagnosis date (or index date in controls). Smoking
was categorised as: (1) never versus ever and (2) pack-years of
smoking (product of years of smoking and packs of cigarettes
per day). Pack-years were dichotomised as never or light
smoking versus heavy smoking (10 vs .10 pack-years based
on epidemiological data from this cohort that demonstrate
increased RA risk with .10 pack-years of smoking.
14 We further
investigated three smoking categories (never, past, current) and
three categories of pack-years ((10, 10–20 and .20 pack-years).
Statistical methods
We verified the Hardy–Weinberg equilibrium for each genotype
among controls in each nested case-control dataset. We
calculated means with standard deviation and medians with
range for continuous covariates stratified by cohort and case/
control status. For categorical covariates, we calculated frequen-
cies and percentages. SAS V.9.1 was used for all analyses (SAS
Institute, Cary, North Carolina, USA). Distributions for HLA-SE
among cases and controls were compared using the x
2 test of
independence. Conditional logistic regression analyses, condi-
tioning on matching factors and adjusting for age at menarche,
menstrual regularity, parity, breastfeeding duration, menopausal
status and postmenopausal hormone use, tested the association
between HLA-SE alleles and RA risk in a general model and in a
dominant model. Unconditional logistic regression analyses,
adjusting for matching factors and covariates, were used to
examine the risks of seropositive and seronegative RA.
Analyses of interaction
We used an additive models of interaction based on disease rates
connected to the ‘‘pie model’’.
29 Rothman showed that
independent risk factors adhere to an additive model and that
biological interaction results in departure from additivity of the
disease rates (see supplementary material). To test for additive
interactions we followed the methods outlined by Lundberg
30
and Andersson,
31 using a 262 factorial design to calculate the
attributable proportion due to interaction (AP), the relative
excess risk due to interaction (RERI) and the synergy index (SI).
A p value of ,0.05 for AP was considered as departure from an
additive model of association. For models where HLA-SE, pack-
years of smoking and smoking status were categorised into
three categories, we calculated indices of additive interaction for
each stratum of exposure compared to the referent category of
non-exposure. The 95% confidence intervals (CIs) were
calculated using the delta method as described previously,
32
which is a straightforward Taylor expansion of the variances
and covariances to derive a probability distribution.
Multiplicative interaction was assessed by adding an interaction
variable (HLA-SE* smoking) to the regression models. A p value
of ,0.05 was considered as evidence for departure from a
multiplicative model of association.
RESULTS
A total of 439 pairs of Caucasian women, each pair being 1 RA
case and a matched control, were included. The cases in the
NHS had a mean (SD) age of 56.7 (9.4) years, compared to 43.1
(5.1) years in the younger NHSII cohort, due to the different
ages targeted for enrolment in each of the cohorts (table 1).
Otherwise, the cases were similar in terms of RA characteristics
with 61% seropositive RA in NHS and 65% seropositive in
NHSII.
Extended report
Ann Rheum Dis 2010;69:54–60. doi:10.1136/ard.2008.102962 55Table 1 shows the distribution of covariates for the RA cases
and their matched controls at the time of RA diagnosis (or index
date for the controls). A higher proportion of RA cases and
controls were postmenopausal at RA diagnosis in NHS
compared to NHSII cohorts. In NHSII a slightly higher
percentage of women with RA were parous compared to their
matched controls (93.9% and 85.7%), but not in the NHS
cohort (91.0% of RA cases and 94.4% of controls).
HLA-SE genotype distributions did not deviate from Hardy–
Weinberg equilibrium. Overall, genotyping call rates were 98.5%
for HLA-SE. The frequency of the HLA-SE was significantly
higher among RA cases than controls (x
2 with 1 degree of
freedom, p,0.001 for pooled NHS/NHSII cohorts). In all, 49
(12.8%) NHS cases had 2 copies of the HLA SE allele as
compared to 24 (6.3%) controls (p,0.001). Similar results were
seen in NHSII participants with nine (18.4%) cases having two
copies of the HLA-SE allele versus one (2.1%) in the controls
(p=0.03). The most common HLA-SE alleles in RA cases were
0401 (13.9%), 0404 (5.4%) and 0101 (9%).
Table 2 includes the results of conditional logistic regression
analyses for RA risk associated with HLA-SE for all RA and from
unconditional logistic regression analyses stratified by seropo-
sitivity. The adjusted model includes pack-years of cigarette
smoking, age at menarche, regularity of menses, parity, breast
feeding, menopausal status and postmenopausal hormone use.
RA risk associated with a single copy of HLA-SE was elevated
(odds ratio (OR) 1.60, 95% CI 1.16 to 2.22) and with a double
copy was markedly elevated (OR 3.78, 95% CI 2.13 to 6.71).
These effects of HLA-SE were limited to seropositive RA (double
HLA-SE OR 4.41, 95% CI 2.53 to 7.68) with no significant
association with seronegative RA.
Interaction results
Table 3 shows the results of analyses in which we tested for
additive and multiplicative interactions between HLA-SE and
smoking, categorised as ever/never smoking or dichotomised at
(10 or .10 pack-years of smoking. There was a 2.14-fold
increased risk of RA (95% CI 1.39 to 3.29) for ever smokers
who carried any HLA-SE compared to the referent group, never
smokers with no HLA-SE, however, there was no evidence for
gene–environment interaction. There was a modest additive
but not multiplicative gene–environment interaction between
ever smoking and the presence of the HLA-SE allele, with the
proportion of risk due to additive interaction (AP) of 0.38 (95%
CI 0.05 to 0.70, p=0.02) for seropositive RA. In contrast, a
2.75-fold elevated risk of RA (95% CI 1.75 to 4.31) and a 3.6-
fold elevated risk of seropositive RA (95% CI 2.26 to 5.78) were
observed among heavy smokers (.10 pack-years) with any
HLA-SE compared to the referent group ((10 pack-years
without HLA-SE). We observed a significant additive, but not
multiplicative, interaction between heavy cigarette smoking
and the presence of the HLA-SE allele, with the proportion of
risk due to additive interaction (AP) of 0.39 (95% CI 0.08 to
0.69, p=0.01) for RA. A stronger additive interaction between
heavy cigarette smoking and HLA-SE allele was observed for
seropositive RA, with AP of 0.50 (95% CI 0.24 to 0.77,
p,0.002), and a significant multiplicative interaction term
(p=0.05).
When stratified by number of copies of HLA-SE there was
strong evidence for increasing risk of RA with each copy of HLA-
SE among heavy smokers, with a 6.6-fold increased risk of RA,
(95% CI 2.49 to 17.46), for heavy smokers with 2 copies of HLA-
SE as compared to the reference group, with evidence for
additive interaction (table 4). The strongest evidence for
additive interaction was for HLA-SE with heavy smoking in
seropositive RA (OR 7.47, 95% CI 2.77 to 20.11), with a
borderline multiplicative interaction (p=0.07). Among HLA-SE
subtypes, the only interaction was between the 0401 allele and
heavy smoking, with evidence for additive interaction
(p=0.005) for all RA. The HLA-SE subtypes of 0401 and 0101
demonstrated significant additive interaction with heavy
smoking (p=0.003 and 0.01, respectively) for seropositive RA.
There was no evidence for multiplicative interactions between
HLA-SE subtypes and heavy smoking (data not shown).
Table 1 Characteristics of rheumatoid arthritis (RA) cases and matched controls in the Nurses’ Health Study (NHS; 1976–2002) and the Nurses’
Health Study II (NHSII; 1989–2003)
Nurses’ Health Study (390 matched pairs) Nurses’ Health Study II (49 matched pairs)
RA cases Controls RA cases Controls
Matching factors
Age, mean (SD) 56.7 (9.4) 57.0 (9.3) 43.1 (5.1) 43.1 (5.1)
Postmenopausal (%) 265 (68.0%) 258 (66.2%) 14 (28.6%) 14 (28.6%)
Current PMH use (%)* 114 (37.1%) 106 (35.9%) 11 (68.8%) 12 (75.0%)
Other characteristics
Ever cigarette smokers (%) 246 (63.1%) 223 (57.2%) 19 (38.8%) 22 (44.9%)
Pack-years among smokers, mean (SD) 23.9 (16.7) 24.1 (20.3) 16.2 (9.1) 10.8 (5.5)
Parous (%) 355 (91.0%) 368 (94.4%) 46 (93.9%) 42 (85.7%)
Breastfed babies >12 months total (%){ 46 (13.7%) 65 (18.4%) 18 (42.9%) 18 (45.0%)
RA features
Mean age at diagnosis, (SD) 56.7 (9.4) – 43.1 (5.1) –
Rheumatoid factor positive (%) 224 (57.4%) – 27 (55.1%) –
Anti-CCP{ positive 86 (47.8%) – 19 (46.3%) –
Seropositive (%) 238 (61.0%) 32 (65.3%)
Rheumatoid nodules, (%) 50 (12.8%) – 6 (12.2%) –
Radiographic changes, (%) 118 (30.3%) – 17 (34.7%) –
Diagnosed by a member of ACR, (%) 322 (84.1%) – 47 (95.9%) –
*Percentage is calculated among postmenopausal women or parous women, with unknown/missing group excluded; for the rest of the variables, percentage was calculated with
missing category included.
{Among parous women.
{Anti-cyclic citrullinated peptide (CCP) antibodies assayed in subset of cases (NHS=180, NHSII=41) with stored blood samples at collected at different points with respect to RA
onset, up to 12 years prior to onset or after diagnosis.
ACR, American College of Rheumatology; PMH, postmenopausal hormone.
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odds for RA were in the 10–20 pack-year and HLA-SE group in
all RA and seropositive RA analyses (table 5). Comparing each
stratum to the referent demonstrated significant additive
interactions for 10–20 pack-year stratum (p=0.008) for all RA
and for 10–20 (p=0.003) and for .20 year strata (p=0.002) for
seropositive RA with a borderline multiplicative interaction
(p=0.09). When stratifying smoking status into never, past, or
current (table 6), there was little evidence for interactions
except a modest additive interaction between past smoking and
HLA-SE for seropositive RA (p=0.04).
DISCUSSION
In this nested case-control study of women, we demonstrate
significant additive and multiplicative interaction between the
HLA-DRB1 shared epitope and heavy cigarette smoking of at
least 10 pack-years. The observed interaction between HLA-SE
and smoking was strongest for seropositive RA with little
evidence for association with seronegative RA. Evidence for
interaction was less evident when smoking status was analysed
as never/ever smoking or never/past/current, suggesting the
importance of considering cumulative ‘‘dose’’ of smoking when
testing for gene–environment interaction in RA.
Interactions between HLA-SE alleles and smoking in RA risk
have been demonstrated in several large epidemiological studies.
In the Epidemiologic Investigations in Rheumatoid Arthritis
(EIRA) study, a strong additive interaction between HLA-SE and
smoking was demonstrated for RF-positive and anti-CCP-positive
RA, but not for seronegative RA
13 19; a 21-fold increased risk of
CCP-positive RA was observed among smokers carrying a double
Table 2 Association between HLA-SE and rheumatoid arthritis (RA) risk in the Nurses’ Health Studies with
stratification by serological status
Model HLA-SE
All RA, unadjusted*
OR (95% CI)
All RA, adjusted{
OR (95% CI)
Seropositive RA,
adjusted{ OR (95% CI)
Seronegative RA,
adjusted{ OR (95% CI)
General None 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
Single SE 1.54 (1.13 to 2.10) 1.60 (1.16 to 2.22) 1.88 (1.34 to 2.65) 1.07 (0.72 to 1.59)
Double SE 3.19 (1.88 to 5.43) 3.78 (2.13 to 6.71) 4.41 (2.53 to 7.68) 1.55 (0.75 to 3.21)
Dominant None 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
Any SE 1.80 (1.35 to 2.41) 1.90 (1.40 to 2.58) 2.25 (1.64 to 3.10) 1.14 (0.78 to 1.65)
*Conditional logistic regression.
{conditional logistic regression, adjusting for smoking (pack-years), parity, breast feeding and menstrual irregularity, and age at
menarche, menopausal status and postmenopausal hormone use at diagnosis.
{Unconditional logistic regression adjusting for year of birth, smoking (pack-years), parity, breast feeding and menstrual
irregularity, and age at menarche, menopausal status and postmenopausal hormone use at blood draw and at diagnosis.
HLA-SE, human leukocyte antigen shared epitope; OR, odds ratio.
Table 3 Gene–environment interaction of human leukocyte antigen shared epitope (HLA-SE) and smoking in the Nurses’ Health Studies
HLA-SE Smoking status All RA Seropositive RA Seronegative RA
OR (95% CI)* OR (95% CI){{ OR (95% CI){1"
None Never 1.00 (reference) 1.00 (reference) 1.00 (reference)
None Ever 0.99 (0.65 to 1.51) 1.05 (0.66 to 1.68) 1.04 (0.64 to 1.69)
Any Never 1.65 (1.05 to 2.61) 1.78 (1.08 to 2.95) 1.18 (0.67 to 2.08)
Any Ever 2.14 (1.39 to 3.29) 2.94 (1.84 to 4.69) 1.23 (0.72 to 2.10)
Additive interaction:
AP (95% CI) 0.23 (20.14 to 0.61) 0.38 (0.05 to 0.70) 0.004 (20.69 to 0.70)
p For interaction padd=0.23 padd=0.02 padd=0.99
RERI 0.49 (20.35 to 1.33) 1.10 (20.02 to 2.22) 0.005 (20.85 to 0.86)
Synergy Index 1.77 (0.50 to 6.25) 2.32 (0.72 to 7.47) 1.02 (0.02 to 47.34)
Multiplicative interaction:
p For interaction pmulti=0.38 pmulti=0.18 pmulti=1.00
OR (95% CI)* OR (95% CI){{ OR (95% CI)
None (10 pack-years smoking 1.00 (reference) 1.00 (reference) 1.00 (reference)
None .10 pack-years smoking 1.10 (0.73 to 1.67) 1.08 (0.67 to 1.72) 1.16 (0.72 to 1.89)
Any (10 pack-years smoking 1.58 (1.08 to 2.33) 1.72 (1.13 to 2.61) 1.09 (0.68 to 1.77)
Any .10 pack-years smoking 2.75 (1.75 to 4.31) 3.61 (2.26 to 5.78) 1.45 (0.81 to 2.56)
Additive interaction:
AP (95% CI) 0.39 (0.08 to 0.69) 0.50 (0.24 to 0.77) 0.13 (20.49 to 0.75)
p For interaction padd=0.01 padd,0.001 padd=0.68
RERI 1.06 (20.06 to 2.17) 1.82 (0.35 to 3.30) 0.19 (20.75 to 1.13)
Synergy index 2.54 (0.81 to 7.97) 3.30 (1.06 to 10.33) 1.74 (0.07 to 42.22)
Multiplicative interaction:
p For interaction pmulti=0.14 pmulti=0.05 pmulti=0.74
padd is the p value for the attributable proportion due to interaction, pmulti is the p value for multiplicative interaction term between binary smoking variable and binary HLA-SE
genotype with 1 degree of freedom.
*Conditional logistic regression, adjusting for parity, breast feeding and menstrual irregularity, and age at menarche, menopausal status and postmenopausal hormone use.
{Unconditional logistic regression adjusting for year of birth, parity, breast feeding and menstrual irregularity, and age at menarche, menopausal status and postmenopausal
hormone use.
{Seropositive RA cases and all controls; 1seronegative RA cases and all controls.
AP, attributable proportion due to interaction, an index of additive interactions between binary smoking variable and binary HLA-SE genotype; RA, rheumatoid arthritis; RERI, relative
excess risk due to interaction.
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19 This finding suggests that these two important
risk factors may interact along one or more biological pathways.
29
The statistical interaction between smoking and HLA-SE alleles in
CCP-positive RA is consistent with the hypothesis that cigarette
smoking modulates the immunogenicity of citrulline and related
peptides in individuals with specific HLA alleles. This hypothesis
has been strengthened by demonstration that smoking can cause
citrullination of peptides in lung macrophages
19 and is associated
with an increased expression of peptidyl arginine deiminase 2
(PADI2) in bronchoalveolar cells.
33 In HLA-DRB1 0401 transgenic
mice, citrullination of certain peptides increases binding to HLA
class II molecules with the SE, triggering immune responses to
citrullinated peptides.
34
Table 4 Gene–environment interaction between HLA-SE (none, single and double copies) and heavy smoking in all rheumatoid arthritis (RA) groups
and in groups stratified by serological status in the Nurses’ Health Studies
HLA-SE
Pack-years
smoking
All RA Seropositive RA Seronegative RA
Cases/controls OR* (95% CI) OR{ (95% CI) Cases/controls OR{ (95% CI) Cases/controls OR1 (95% CI)
0 (10 119/161 1.00 (reference) 1.00 (reference) 64/161 1.00 (reference) 55/161 1.00 (reference)
1 (10 86/94 1.26 (0.85 to 1.88) 1.33 (0.88 to 2.00) 52/94 1.36 (0.87 to 2.15) 34/94 1.08 (0.65 to 1.79)
2 (10 32/19 2.61 (1.37 to 4.97) 2.96 (1.51 to 5.80) 25/19 3.56 (1.81 to 7.02) 7/19 1.21 (0.47 to 3.08)
0 .10 86/103 1.13 (0.75 to 1.69) 1.07 (0.70 to 1.62) 44/103 1.08 (0.68 to 1.73) 42/103 1.16 (0.72 to 1.89)
1 .10 78/46 2.26 (1.42 to 3.62) 2.24 (1.38 to 3.62) 57/46 3.14 (1.91 to 5.17) 21/46 1.25 (0.67 to 2.32)
2 .10 24/6 5.43 (2.14 to 13.77) 6.60 (2.49 to 17.46) 18/6 7.47 (2.77 to 20.11) 6/6 2.97 (0.90 to 9.79)
Additive:
AP1 (95% CI) 0.39 (0.05 to 0.72) 0.38 (0.03 to 0.73) 0.54 (0.26 to 0.82) 0.01 (20.75 to 0.77)
p For interaction 0.02 0.04 ,0.001 0.98
RERI 0.88 (20.11 to 1.86) 0.84 (20.16 to 1.85) 1.70 (0.29 to 3.11) 0.01 (20.94 to 0.97)
Synergy index 3.26 (0.52 to 20.25) 3.15 (0.48 to 20.54) 4.81 (0.71 to 32.54) 1.06 (0.02 to 54.35)
AP2 (95% CI) 0.50 (20.03 to 1.02) 0.54 (0.05 to 1.04) 0.51 (20.03 to 1.06) 0.54 (20.12 to 1.20)
p For interaction 0.06 0.03 0.07 0.11
RERI 2.70 (22.34 to 7.73) 3.57 (22.75 to 9.90) 3.83 (23.59 to 11.24) 1.60 (22.00 to 5.20)
Synergy index 2.56 (0.63 to 10.40) 2.77 (0.69 to 11.06) 2.45 (0.62 to 9.72) 5.32 (0.11 to 252.71)
Multiplicative:
p For interaction1 0.13 0.20 0.07 0.52
*Conditional logistic regression.
{Conditional logistic regression, adjusting for parity, breast feeding and menstrual irregularity, and age at menarche, menopausal status and postmenopausal hormone use at diagnosis.
{Unconditional logistic regression adjusting for year of birth, parity, breast feeding and menstrual irregularity, and age at menarche, menopausal status and postmenopausal hormone
use at blood draw and at diagnosis.
1p Value calculated from HLA-SE6pack-years interaction term.
AP, attributable proportion due to interaction, an index of additive interactions between binary smoking variable and binary HLA-SE genotype; RERI, relative excess risk due to interaction.
Table 5 Gene–environment interaction between HLA-SE (none, any) and pack-years of smoking ((10, 10–20, .20) in all rheumatoid arthritis (RA)
groups and in groups stratified by serological status in the Nurses’ Health Studies
HLA-SE
Pack-years
smoking
All RA Seropositive RA Seronegative RA
Cases/controls OR* (95% CI) OR{ (95% CI) Cases/controls OR{ (95% CI) Cases/controls OR{ (95% CI)
None (10 119/161 1.00 (reference) 1.00 (reference) 64/161 1.00 (reference) 55/161 1.00 (reference)
None 10 to 20 25/33 0.98 (0.54 to 1.77) 1.04 (0.56 to 1.93) 15/33 1.14 (0.57 to 2.26) 10/33 0.93 (0.43 to 2.04)
None .20 61/70 1.22 (0.78 to 1.91) 1.13 (0.71 to 1.80) 29/70 1.04 (0.61 to 1.79) 32/70 1.27 (0.74 to 2.17)
Any (10 118/113 1.49 (1.03 to 2.17) 1.58 (1.08 to 2.32) 77/113 1.72 (1.13 to 2.60) 41/113 1.09 (0.68 to 1.77)
Any 10 to 20 29/12 3.42 (1.60 to 7.28) 3.55 (1.62 to 7.78) 21/12 4.31 (1.97 to 9.42) 8/12 1.76 (0.67 to 4.64)
Any .20 73/40 2.50 (1.54 to 4.07) 2.52 (1.53 to 4.14) 54/40 3.39 (2.02 to 5.69) 19/40 1.35 (0.71 to 2.57)
Additive:
AP1 (95% CI) 0.57 (0.20 to 0.94) 0.54 (0.14 to 0.94) 0.57 (0.20 to 0.95) 0.42 (20.29 to 1.13)
p For interaction 0.003 0.008 0.003 0.25
RERI 1.94 (20.61 to 4.49) 1.93 (20.81 to 4.66) 2.46 (20.81 to 5.72) 0.74 (21.06 to 2.53)
Synergy index 5.10 (0.72 to 36.36) 4.09 (0.74 to 22.56) 3.89 (0.86 to 17.64) 31.55 (0.00 to 2.072E19)
Multiplicative:
p For interaction 0.09 0.13 0.13 0.39
Additive:
AP2 (95% CI) 0.32 (20.05 to 0.68) 0.32 (20.05 to 0.70) 0.48 (0.17 to 0.79) 20.01 (20.80 to 0.78)
p For interaction 0.09 0.09 0.002 0.98
RERI 0.79 (20.36 to 1.93) 0.81 (20.37 to 1.99) 1.63 (0.04 to 3.22) 20.02 (21.07 to 1.04)
Synergy index 2.10 (0.65 to 6.80) 2.15 (0.64 to 7.23) 3.16 (0.89 to 11.21) 0.96 (0.05 to 19.07)
Multiplicative:
p For interaction 0.33 0.30 0.09 0.95
*Conditional logistic regression.
{Conditional logistic regression, adjusting for smoking (pack-years), parity, breast feeding and menstrual irregularity, and age at menarche, menopausal status and postmenopausal
hormone use at diagnosis.
{Unconditional logistic regression adjusting for year of birth, smoking (pack-years), parity, breast feeding and menstrual irregularity, and age at menarche, menopausal status and
postmenopausal hormone use at blood draw and at diagnosis.
AP, attributable proportion due to interaction, an index of additive interactions between binary smoking variable and binary HLA-SE genotype; RERI, relative excess risk due to interaction.
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58 Ann Rheum Dis 2010;69:54–60. doi:10.1136/ard.2008.102962Evidence for gene–environment interaction between HLA-SE
and smoking in seropositive RA risk was seen in patients with
undifferentiated arthritis at the Leiden Early Arthritis Clinic.
Among the participants who were HLA-SE positive, ever
smoking significantly increased the OR for development of
CCP-positive RA from 3.3 to 8.0 (p=0.002 for multiplicative
interaction)
21; HLA-SE and ever smoking also increased the OR
of CCP antibodies, with evidence for additive but not multi-
plicative interaction.
20 35 A Danish case-control study of HLA-SE
interactions with RA epidemiological risk factors, did not
demonstrate any significant multiplicative interaction for
HLA-SE* smoking, however, HLA-SE homozygotes had a 52-
fold increased risk of CCP-positive RA compared to non-carrier/
never smokers. Testing for additive interaction was not
performed. In contrast, a significant HLA-SE* smoking interac-
tion was demonstrated in the Iowa Women’s Health Study, an
older Caucasian female cohort in which smoking was associated
with increased risk of RA only among subjects who were HLA-
SE negative, but not among subjects who were HLA-SE
positive.
36 The reasons for this discrepancy are unknown,
although it may relate to the older age at RA onset or the
small sample size (116 cases) in that cohort. A case-only analysis
combining data from three large US populations was unable to
confirm an interaction between HLA-SE alleles and cigarette
smoking in relation to presence of CCP antibodies but smoking
status was defined only as never/ever smoking.
22 In one cohort
with information on pack-years of smoking, there was an
independent effect of smoking on the presence of CCP among
heavy smokers (.20 pack-years).
Strengths of this study include the prospective collection of
exposure information prior to the onset of RA, the detailed
smoking data collected every 2 years and availability of high-
resolution HLA genotyping. Limitations include the lack of data
on CCP antibody status, as most cases were diagnosed prior to
the widespread usage of this test, and absence of plasma samples
for CCP testing in about half the cases. However, RF status was
available from medical record reviews, and other gene–environ-
ment interaction studies demonstrate similar relationships for
RF-positive and CCP-positive phenotypes.
13 19 The rate of
seropositive RA in this study (60%) is similar to that reported
from a large US registry study, the National Databank
(n=14 000)withpatientsrecruitedfromrheumatologypractices
across the US.
37 Limited generalisability of NHS a concern, as the
NHS cohorts are comprised of middle to older aged women with
high educational levels and with primarily Caucasian heritage.
However, an advantage of similar ethnic background in genetic
studies is a lower potential for population stratification.
This study of gene–environment interactions in RA in a cohort
of Caucasian US women demonstrates a significant additive and
multiplicative interaction between the strongest genetic risk
factor for RA, the HLA-SE, and heavy cigarette smoking .10
pack-years, the strongest environmental risk factor for RA, for
seropositive but not seronegative RA. We demonstrate only
additive interaction between smoking categorised as never/ever
smokedorasthreecategories (never,past,current)with theHLA-
SE and seropositive RA; however, if smoking is classified by dose
(as pack-years), we demonstrate additive and multiplicative
interaction for seropositive RA. This illustrates the importance of
considering the dose effects of environmental and genetic factors
in gene–environment interaction studies. Additionally, it lends
evidence to the theory that seropositive and seronegative RA
have different risk factors and pathogenic pathways.
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Table 6 Gene–environment interaction between HLA-SE (none, any) and smoking status (never, past, current) in all rheumatoid arthritis (RA) groups
and in groups stratified by serological status in the Nurses’ Health Studies
HLA-SE
Smoking
status
All RA Seropositive RA Seronegative RA
Cases/controls OR* (95% CI) OR{ (95% CI) Cases/controls OR{ (95% CI) Cases/controls OR{ (95% CI)
None Never 81/111 1.00 (reference) 1.00 (reference) 42/111 1.00 (reference) 39/111 1.00 (reference)
None Past 92/110 1.13 (0.74 to 1.73) 1.03 (0.66 to 1.61) 50/110 1.11 (0.68 to 1.83) 42/110 1.05 (0.62 to 1.77)
None Current 32/46 0.90 (0.51 to 1.59) 0.90 (0.49 to 1.64) 15/46 0.90 (0.45 to 1.81) 17/46 1.03 (0.52 to 2.06)
Any Never 85/77 1.60 (1.03 to 2.49) 1.67 (1.05 to 2.63) 54/77 1.78 (1.08 to 2.95) 31/11 1.18 (0.70 to 2.09)
Any Past 99/60 2.25 (1.43 to 3.52) 2.23 (1.40 to 3.56) 71/60 3.03 (1.83 to 5.03) 28/60 1.28 (0.71 to 2.33)
Any Current 38/27 1.89 (1.03 to 3.47) 1.91 (1.03 to 3.55) 27/27 2.71 (1.41 to 5.19) 11/27 1.10 (0.49 to 2.48)
Additive:
AP1 (95% CI) 0.23 (20.15 to 0.61) 0.24 (20.15 to 0.63) 0.38 (0.03 to 0.73) 0.04 (20.68 to 0.74)
p For interaction 0.23 0.22 0.04 0.91
RERI 0.52 (20.40 to 1.44) 0.54 (20.41 to 1.48) 1.14 (20.17 to 2.44) 0.06 (21.31 to 1.08)
Synergy index 1.71 (0.54 to 5.40) 1.77 (0.52 to 6.08) 2.27 (0.71 to 7.27) 1.24 (0.02 to 67.47)
Multiplicative:
p For interaction 0.48 0.41 0.24 0.93
Additive:
AP2 (95% CI) 0.21 (20.35 to 0.77) 0.18 (20.42 to 0.78) 0.38 (20.10 to 0.85) 20.10 (21.22 to 1.02)
p For interaction 0.47 0.55 0.12 0.86
RERI 0.39 (20.80 to 1.59) 0.35 (20.91 to 1.60) 1.02 (20.66 to 2.70) 20.11 (20.88 to 0.99)
Synergy index 1.80 (0.26 to 12.58) 1.62 (0.25 to 10.36) 2.49 (0.46 to 13.63) 0.49 (0.00 to 2327.19)
Multiplicative:
p For interaction 0.51 0.58 0.28 0.85
*Conditional logistic regression.
{Conditional logistic regression, adjusting for parity, breast feeding and menstrual irregularity, and age at menarche, menopausal status and postmenopausal hormone use at
diagnosis.
{Unconditional logistic regression adjusting for year of birth, parity, breast feeding and menstrual irregularity, and age at menarche, menopausal status and postmenopausal
hormone use at blood draw and at diagnosis.
AP, attributable proportion due to interaction, an index of additive interactions between binary smoking variable and binary HLA-SE genotype; RERI, relative excess risk due to interaction.
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